(Q47978551)

7 February 2018

title

Safety and efficacy of ranirestat in patients with mild-to-moderate diabetic sensorimotor polyneuropathy (English)

1 reference

7 February 2018

4

Vera Bril

1 reference

7 February 2018

Michael Polydefkis

1

1 reference

7 February 2018

Joseph Arezzo

2

1 reference

7 February 2018

Marshall Nash

3

1 reference

7 February 2018

Aziz Shaibani

5

1 reference

7 February 2018

Robert J Gordon

6

1 reference

7 February 2018

Kate L Bradshaw

7

1 reference

7 February 2018

Roderick W J Junor

8

1 reference

7 February 2018

Ranirestat Study Group

9

1 reference

7 February 2018

publication date

27 August 2015

1 reference

7 February 2018

Journal of the Peripheral Nervous System

published in

1 reference

7 February 2018

volume

20

1 reference

7 February 2018

issue

4

1 reference

7 February 2018

page(s)

363-371

1 reference

7 February 2018

Aldose reductase inhibition by AS-3201 in sural nerve from patients with diabetic sensorimotor polyneuropathy

cites work

1 reference

Ranirestat for the management of diabetic sensorimotor polyneuropathy

21 January 2018

1 reference

Lipid-lowering therapy and peripheral sensory neuropathy in type 2 diabetes: the Fremantle Diabetes Study.

21 January 2018

1 reference

A Multiple Comparison Procedure for Comparing Several Treatments with a Control

21 January 2018

1 reference

Longitudinal assessment of diabetic polyneuropathy using a composite score in the Rochester Diabetic Neuropathy Study cohort

21 January 2018

1 reference

Distal symmetric polyneuropathy: a definition for clinical research: report of the American Academy of Neurology, the American Association of Electrodiagnostic Medicine, and the American Academy of Physical Medicine and Rehabilitation

21 January 2018

1 reference

The evolving natural history of neurophysiologic function in patients with well-controlled diabetes

21 January 2018

1 reference

Complications: neuropathy, pathogenetic considerations

21 January 2018

1 reference

Aldose reductase, still a compelling target for diabetic neuropathy

21 January 2018

1 reference

Effects of long-term treatment with ranirestat, a potent aldose reductase inhibitor, on diabetic cataract and neuropathy in spontaneously diabetic torii rats

21 January 2018

1 reference

Natural history of peripheral neuropathy in patients with non-insulin-dependent diabetes mellitus

21 January 2018

1 reference

The time course of epidermal nerve fibre regeneration: studies in normal controls and in people with diabetes, with and without neuropathy

21 January 2018

1 reference

Interplay of sorbitol pathway of glucose metabolism, 12/15-lipoxygenase, and mitogen-activated protein kinases in the pathogenesis of diabetic peripheral neuropathy

21 January 2018

1 reference

Prevalence and impact on quality of life of peripheral neuropathy with or without neuropathic pain in type 1 and type 2 diabetic patients attending hospital outpatients clinics

21 January 2018

1 reference

Efficacy and safety of antioxidant treatment with α-lipoic acid over 4 years in diabetic polyneuropathy: the NATHAN 1 trial

21 January 2018

1 reference

New Tables for Multiple Comparisons with a Control

21 January 2018

1 reference

Factors That Impact Symptomatic Diabetic Peripheral Neuropathy in Placebo-Administered Patients From Two 1-Year Clinical Trials

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.1111/JNS.12138

1 reference

7 February 2018

1 reference

7 February 2018